TISIDB

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein Membrane raft Single-pass type I membrane protein
Domain	PF01839 FG-GAP repeat PF00357 Integrin alpha cytoplasmic region PF08441 Integrin alpha PF00092 von Willebrand factor type A domain
Function	Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. It probably recognizes the R-G-D peptide in C3b. Integrin ITGAM/ITGB2 is also a receptor for fibrinogen, factor X and ICAM1. It recognizes P1 and P2 peptides of fibrinogen gamma chain. Regulates neutrophil migration (PubMed:28807980). In association with beta subunit ITGB2/CD18, required for CD177-PRTN3-mediated activation of TNF primed neutrophils (PubMed:21193407). May regulate phagocytosis-induced apoptosis in extravasated neutrophils (By similarity). May play a role in mast cell development (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002224 toll-like receptor signaling pathway GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0007229 integrin-mediated signaling pathway GO:0007398 ectoderm development GO:0010668 ectodermal cell differentiation GO:0030198 extracellular matrix organization GO:0031349 positive regulation of defense response GO:0034142 toll-like receptor 4 signaling pathway GO:0043062 extracellular structure organization GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0050900 leukocyte migration
Molecular Function	GO:0001948 glycoprotein binding GO:0046982 protein heterodimerization activity
Cellular Component	GO:0008305 integrin complex GO:0043235 receptor complex GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway hsa04145 Phagosome hsa04514 Cell adhesion molecules (CAMs) hsa04610 Complement and coagulation cascades hsa04640 Hematopoietic cell lineage hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-6798695: Neutrophil degranulation R-HSA-449147: Signaling by Interleukins R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168898: Toll-Like Receptors Cascades

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04015 Rap1 signaling pathway
hsa04145 Phagosome
hsa04514 Cell adhesion molecules (CAMs)
hsa04610 Complement and coagulation cascades
hsa04640 Hematopoietic cell lineage
hsa04670 Leukocyte transendothelial migration
hsa04810 Regulation of actin cytoskeleton

Reactome

R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-216083: Integrin cell surface interactions
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-449147: Signaling by Interleukins
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168898: Toll-Like Receptors Cascades

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ITGAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ITGAM and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19414774	Lung carcinoma	Inhibit immunity (T cell function)	A natural counterpart of CD11b(high)Ia(low) DCs was identified in tumor tissue, and CD11b(high)Ia(low) DCs sorted from 3LL lung cancer tissue expressed arginase I and inhibited T cell response.
23562161	Colon Carcinoma	Inhibit immunity	Manipulations preventing tumor infiltration by CD11c(+)CD11b(+)Ly6C(hi) cells,?such as the local overexpression of ectonucleotidases, the blockade of purinergic receptors, or the neutralization of CD11b, abolished the immune?system-dependent antitumor activity of anthracyclines.
24965046	Glioma	Inhibit immunity	Intermittent metronomic cyclophosphamide scheduling strongly increased glioma-associated CD11b+ immune cells but not CD11b+Gr1+ myeloid-derived suppressor cells, while bone marrow and spleen reservoirs of the suppressor cells were decreased.
24907113	melanoma	Inhibit immunity	Furthermore, silencing COX-2 in murine 4T1 tumor cells reduced the accumulation of CD11b(+)Gr1(+) MDSCs in the spleen, resulting in concomitant improved in vivo clearance of NK-cell sensitive YAC-1 cells.
29636751	colorectal carcinoma	Inhibit immunity	MDSCs comprise a heterogeneous population of immature myeloid cells that can be distinct in two subtypes: CD11b+Ly6G+Ly6Clow with granulocytic phenotype (G-MDSCs) and CD11b+Ly6G-Ly6Chigh with monocytic phenotype (M-MDSCs).
29602801	mesothelioma	Inhibit immunity	Characterization of the whole blood at diagnosis identified similar, circulating, immunosuppressive CD11b+CD15+HLADR- granulocytes at increased frequency compared with healthy controls.
20042467	Metastatic Malignant Neoplasm in the Liver	Inhibit immunity (T cell function)	Liver CD11b(+)Gr1(+) cells are highly suppressive of T cell activation, proliferation, and cytotoxicity and induce the development of Tregs.
22955317	Non-Small Cell Lung Carcinoma	Inhibit immunity (T cell function)	Patients with NSCLC had a significantly higher ratio of CD11b(+)CD14(+) cells than healthy subjects, which was correlated with poor performance status and poor response to chemotherapy. Isolated CD11b(+)CD14(+) cells suppressed CD8(+) T-cell proliferation and IFN-γ production, and the former effect was attenuated by the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine hydrochloride, arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA), and blocking antibodies for IL-4Rα(+) and IL-10.
20427766	Ovarian Carcinoma	Promote immunity	However, we show that CD11b(+)Gr-1(+) cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stages of disease are immunostimulatory rather than being immunosuppressive. Moreover, like dendritic cells, immunostimulatory CD11b(+)Gr-1(+) cells can strongly cross-prime, augmenting the proliferation of functional CTLs via signaling through the expression of costimulatory molecule CD80.
25183499	melanoma	Inhibit immunity	CD11b(+) myeloid cells from PLX4720-treated tumors also exhibited decreased immunosuppressive function on a per-cell basis.
25085111	lung carcinoma	Inhibit immunity	CD11b+MC were responsible for CD80 down-regulation on HBC and resulted in impaired T cell stimulation by HBC. CD80 loss on HBC was dependent on CD11b MC CD11b expression and STAT3 activity.
16849468	lymphoma	Inhibit immunity	However, CD11b(+) cells accumulated in primary ocular tumors and contained potent immunosuppressive activity when assayed in vitro. Thus, CD11b(+) cells that accumulate within the eye as tumors develop in the a.c. may contribute to immune evasion by primary ocular tumors by inhibiting CTLs within the eye

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ITGAM in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ITGAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.299	0.346
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.295	0.768
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.3	0.686
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.391	0.443
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.745	0.671
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.062	0.979
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.261	0.599
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.098	0.941
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.649	0.655
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.513	0.215
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.306	0.185
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.264	0.141

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ITGAM in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	11.8	-4.7	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	0	12.5	0.485
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGAM. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ITGAM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ITGAM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ITGAM
Name	integrin, alpha M (complement component 3 receptor 3 subunit)
Aliases	CD11b; CR3A; integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macropha ......
Chromosomal Location	16p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ITGAM collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ITGAM